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Objectives The goal of this study was to evaluate the ability of noninvasive programmed stimulation (NIPS) after ventricular
tachycardia (VT) ablation to identify patients at high risk of recurrence.
Background Optimal endpoints for VT ablation are not well defined.
Methods Of 200 consecutive patients with VT and structural heart disease undergoing ablation, 11 had clinical VT induc-
ible at the end of ablation and 11 recurred spontaneously. Of the remaining 178 patients, 132 underwent NIPS
through their implantable cardioverter-defibrillator 3.1  2.1 days after ablation. At 2 drive cycle lengths, single,
double, and triple right ventricular extrastimuli were delivered to refractoriness. Clinical VT was defined by com-
parison with 12-lead electrocardiograms and stored implantable cardioverter-defibrillator electrograms from
spontaneous VT episodes. Patients were followed for 1 year.
Results Fifty-nine patients (44.7%) had no VT inducible at NIPS; 49 (37.1%) had inducible nonclinical VT only; and
24 (18.2%) had inducible clinical VT. Patients with inducible clinical VT at NIPS had markedly decreased
1-year VT-free survival compared to those in whom no VT was inducible (30% vs. 80%; p  0.001), in-
cluding 33% recurring with VT storm. Patients with inducible nonclinical VT only, had intermediate 1-year
VT-free survival (65%).
Conclusions When patients with VT and structural heart disease have no VT or nonclinical VT only inducible at the end of ab-
lation or their condition is too unstable to undergo final programmed stimulation, NIPS should be considered in
the following days to further define risk of recurrence. If clinical VT is inducible at NIPS, repeat ablation may be
considered because recurrence over the following year is high. (J Am Coll Cardiol 2012;59:1529–35) © 2012
by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.026Optimal endpoints for ablation of ventricular tachycardia (VT)
in patients with structural heart disease are not well defined.
Typically, acute success is defined by noninducibility with
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2011, accepted January 2, 2012.programmed stimulation at the end of ablation of: 1) all clinical
VTs; 2) all VTs with cycle lengths greater than or equal to the
clinical cycle lengths; or 3) all VTs. However, even when these
endpoints are achieved, subsequent recurrence of VT is not
uncommon (1–4). Therefore, new endpoints that can predict
greater freedom from long-term VT recurrence are needed.
See page 1536
There are several reasons why programmed stimulation at
the end of ablation may fail to predict VT recurrence. First,
changes in antiarrhythmic drugs are frequently made after
ablation, particularly related to dosing or discontinuation of
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tion of re-entrant arrhythmias with
programmed stimulation is probabi-
listic, and reproducibility is far from
perfect (5). Third, changes in
autonomic tone and/or the use of
general anesthesia may affect VT
inducibility (6,7). Fourth, ablation
lesions may either expand as a result
of disruption of microcirculation,
with consequent myocyte loss, or
regress secondary to healing and res-
olution of edema (8,9). Fifth, the
patient’s condition may be too unstable to subject to rigorous
programmed stimulation after a prolonged ablation procedure.
Noninvasive programmed stimulation (NIPS) can be per-
formed via a patient’s implantable cardioverter-defibrillator
(ICD) in the week after ablation to overcome some of these
limitations. We hypothesized that among those without clin-
ical VT inducible at the end of ablation and without sponta-
neous VT recurrence, inducibility of clinical VT at NIPS
would identify an additional subgroup of patients at high risk
of long-term VT recurrence.
Methods
Study population. We studied consecutive patients with
ustained VT and structural heart disease who were referred
o the Hospital of the University of Pennsylvania for
blation between January 2008 and April 2010. Patients
ith idiopathic VT were excluded. All patients provided
ritten informed consent, and all procedures conformed to
he University of Pennsylvania Health System guidelines.
lectrophysiology study and ablation. Conscious seda-
ion was used whenever possible. General anesthesia with an
nhaled anesthetic, most commonly sevoflurane, was used
hen necessary for ventilation, oxygenation, or patient
omfort. In addition, general anesthesia was typically used
uring epicardial mapping and ablation. Electroanatomic
apping (CARTO, Biosense Webster, Inc., Diamond Bar,
alifornia) was performed during sinus or paced rhythm to
efine areas of low voltage and abnormal electrograms,
onsistent with scar (10). Programmed stimulation was
erformed and induced VTs were compared with those
ccurring spontaneously. When a 12-lead electrocardiogram
ECG) of spontaneous VT was available (62% of cases),
linical VT was defined by match in all 12 ECG leads.
hen a 12-lead ECG of spontaneous VT was not available
38% of cases), clinical VT was defined by match in
ear-field and far-field ICD electrogram morphology, as
ell as cycle length within 30 ms, of stored electrograms
rom spontaneous VT episodes. Every spontaneously occur-
ing VT was considered clinical; thus, a single patient could
ave multiple clinical VTs. Special attention was paid to
limination of clinical VT. In addition, all mappable VT
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
ECG  electrocardiogram
ICD  implantable
cardioverter-defibrillator
NIPS  noninvasive
programmed stimulation
VT  ventricular
tachycardiand VT with cycle length 250 ms were also consideredelevant and routinely targeted for ablation. When hemo-
ynamically tolerated, entrainment mapping was used to
efine critical components of the VT circuit. If VT was not
appable, substrate modification was performed with linear
nd/or cluster lesions targeting sites identified by pacemap-
ing and late potentials. Ablation was typically performed
sing an irrigated ablation catheter (Thermocool [Biosense
ebster, Inc.] or Chilli [Boston Scientific, Boston, Massa-
husetts]) using powers up to 50 W with a goal 12- to
5-ohm impedance drop. Epicardial mapping and ablation
ere performed when 12-lead ECG of VT suggested an
picardial exit (11) and/or endocardial ablation failed to
liminate targeted VT. After ablation, programmed stimu-
ation was repeated in patients who were medically stable,
ith up to 3 ventricular extrastimuli delivered from 2 sites at
pacing cycle lengths. Ablation was repeated in patients
ith inducible clinical VT at the end of the first ablation
nd in those with spontaneous recurrence before NIPS.
oninvasive programmed stimulation. In the absence of
clinical VT being inducible at the end of ablation or
spontaneous VT recurrence, NIPS was typically performed
within several days of ablation, before hospital discharge. In
the fasting state, with intermittent boluses of propofol
titrated to deep sedation, single, double, and then triple
extrastimuli were delivered to refractoriness at drive trains of
600 and 400 ms, via the right ventricular ICD lead. In 3
patients who did not have ICDs, programmed stimulation
was performed via a quadripolar catheter advanced through
the femoral vein to the right ventricle. Response to NIPS
was categorized as “clinical VT inducible” if any sustained,
monomorphic VT was induced matching any of the sponta-
neous VT on 12-lead ECG or on ICD electrograms when
12-lead ECG of spontaneous VT was not available. Response
was categorized as “nonclinical VT inducible” if only sustained
monomorphic VT not matching any of the clinical VTs was
induced. Finally, if no sustained monomorphic VT could be
induced, the response was categorized as “no VT inducible.”
Patients with inducible nonsustained monomorphic VT, poly-
morphic VT, or ventricular fibrillation only were included in
the no VT inducible group. The NIPS results were used for
prognostic purposes and to optimize ICD programming.
Detection rates were adjusted to detect induced VTs. If
antitachycardia pacing (ATP) was demonstrated to be effective
at NIPS, then specific programming to incorporate effective
ATP was performed. In the remaining patients in whom ATP
was not effective at NIPS or could not be tested because of
noninducibility, 1 or 2 bursts of ATP to attempt to terminate
spontaneous episodes without delaying shocks was typically
programmed. Additional ablation was not performed on the
basis of NIPS results.
Clinical follow-up. Patients were routinely evaluated at 4
to 8 weeks after ablation and then at 3- to 6-month
intervals. For patients not followed at our institution,
referring cardiologists were contacted and ICD interroga-
tions reviewed to determine arrhythmia recurrence. Tele-
phone interviews were performed at 6- to 12-month inter-
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April 24, 2012:1529–35 NIPS After VT Ablation to Predict Recurrencevals with patients or family members to confirm the absence
of arrhythmia symptoms. The Social Security Death Index
was also queried.
Statistical analysis. Continuous variables are expressed as
mean  SD, and categorical variables are expressed as
percentages. The Student t test and Pearson’s chi-square
test were used to compare continuous and dichotomous
variables, respectively. We constructed Kaplan-Meier curves
to illustrate 1-year survival free of VT and compared those
with clinical VT inducible at NIPS to those with nonclinical
VT inducible and those with no VT inducible, using a
log-rank test. This analysis was repeated in the subgroup of
patients with ischemic cardiomyopathy only and then with
nonischemic cardiomyopathy only. Multivariate logistic re-
gression was used to identify predictors of time to VT recur-
rence. Variables subjected to univariate screening included age,
left ventricular ejection fraction, ischemic cardiomyopathy,
prior ablation, VT storm (3 episodes of VT within 24 h),
amiodarone pre-ablation, high-dose (400 mg daily) amioda-
rone pre-ablation, general anesthesia, clinical VT inducible and
sustained, clinical VT hemodynamically tolerated, number of
VTs targeted, epicardial ablation, no programmed stimulation
at end of ablation, clinical VT inducible at end of ablation,
nonclinical VT inducible at end of ablation, NIPS not per-
formed, clinical VT inducible at NIPS, nonclinical VT induc-
ible at NIPS, slow VT (cycle length 300 ms) inducible at
NIPS, VT inducible with single or double extrastimuli, poly-
morphic VT or ventricular flutter inducible at NIPS, and
Figure 1 Patient Flow After VT Ablation
VT  ventricular tachycardia; NIPS  noninvasive programmed stimulation.amiodarone dose reduced after ablation. Variables showing
marginal associations with recurrence on univariate testing
(p  0.10) were assessed in a multivariate model.
Analyses were performed using SPSS version 16.0 (SPSS
nc., Chicago, Illinois). We considered p values 0.05 to
ndicate statistical significance.
esults
aseline and procedural characteristics. Of 200 consec-
tive patients with VT and structural heart disease under-
oing ablation between September 2008 and April 2010, a
otal of 167 underwent programmed stimulation at the end
f ablation, with clinical VT inducible in 11 patients (Fig. 1).
he remaining 33 patients were not sufficiently medically
table to undergo final programmed stimulation. Eleven pa-
ients exhibited recurrence of spontaneous VT in the days after
blation. Of the remaining 178 patients, 132 (74%) underwent
IPS a mean of 3.1 2.1 days after ablation. Reasons for not
erforming NIPS included unstable medical condition (n 
6), death before NIPS (n  6), and patient and/or treating
hysician preference (n  14). Compared to those in whom
IPS was not performed, patients undergoing NIPS were
ore likely to have been placed under general anesthesia
uring ablation, more likely to undergo final programmed
timulation at the end of ablation, and less likely to have any VT
nducible at the end of ablation (p  0.01, 0.05, and 0.01,
espectively) (Table 1).
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NIPS After VT Ablation to Predict Recurrence April 24, 2012:1529–35NIPS results. No VT was inducible at NIPS in 59 (44.7%)
atients. Nonclinical VT was inducible in 49 (37.1%) and
linical VT inducible in 24 (18.2%) patients. Patients with
nducible clinical VT were more likely to be treated with
miodarone, more likely to be treated with high-dose
miodarone, and more likely to have their amiodarone dose
educed after ablation, compared to those in whom no
T was inducible (p  0.01, 0.01, and 0.01, respectively)
Baseline and AblationCharacteristics of Patients StratifiedAccording to Whe her NIPS W s P rformed
Table 1
Baselin and Ablation
Characteristics of Patients Stratified
According to Whether NIPS Was Performed
Characteristics
NIPS
Performed
(n  132)
NIPS Not
Performed
(n  68) p Value
Baseline characteristics
Male 92.4 89.7 0.6
Age (yrs) 64.6 12.6 65.4 12.6 0.7
Left ventricular ejection fraction 32.1 14.3 28.0 14.5 0.1
Cardiomyopathy etiology
Ischemic 64.4 58.8 0.4
Nonischemic 31.8 38.3
Right ventricular 3.8 2.9 0.4
Prior ablation 40.2 29.4 0.2
VT storm 50.1 50.0 0.9
Antiarrhythmic drug use
Amiodarone 68.2 54.4 0.1
Amiodarone 400 mg daily 51.5 47.1 0.7
Previous amiodarone, now
intolerant
11.4 14.7 0.5
Non-amiodarone
antiarrhythmic drug alone
or in combination with
amiodarone
62.9 61.8 0.9
Amiodarone dose reduced
after ablation
65.9 57.4 0.3
Procedural characteristics
General anesthesia 38.6 20.6 0.01
Clinical VT inducible and
sustained
86.4 75.0 0.1
Clinical VT hemodynamically
tolerated
43.1 29.4 0.1
Morphologically distinct VT
targeted for ablation
2.7 1.9 2.5 1.9 0.5
Endocardial ablation only 72.7 85.3 0.1
Endocardial and epicardial
ablation
27.3 14.7
No programmed stimulation
performed at end of
ablation
13.6 22.1 0.05
Programmed stimulation
performed at end of
ablation
Clinical VT inducible 0.0 14.7
Nonclinical VT inducible 25.8 20.6 0.7
No VT inducible 60.2 42.7 0.01
Additional ablation procedure
within same
hospitalization
9.8 20.5 0.5
Values are % or mean  SD.
NIPS  noninvasive programmed stimulation; VT ventricular tachycardia.Table 2). Of the 24 patients with clinical VT induced at oIPS, 6 did not undergo programmed stimulation at the
nd of ablation, 6 had nonclinical VT induced at the end of
he ablation, and 12 had no VT induced.
linical follow-up. All patients were followed for 1 year
fter ablation or until censoring at the time of death or heart
ransplantation. Among patients in whom clinical VT was
nducible at NIPS, 21% died during follow-up, compared
ith 24% among those in whom nonclinical VT was
nducible and 3% among those in whom no VT was
nducible (p  0.01 for comparison between clinical induc-
ble VT and no inducible VT). One patient in the nonclini-
al VT-inducible group and one patient in the no VT-
nducible group underwent left ventricular assist device
mplantation. One patient in the clinical VT-inducible
roup and one patient in the nonclinical VT-inducible
roup underwent heart transplantation.
Using univariate testing, lower left ventricular ejection
raction, no programmed stimulation at the end of ablation,
nducible clinical VT at the end of ablation, NIPS not
erformed, inducible clinical VT at NIPS, inducible slow
T (cycle length 300 ms) at NIPS, and amiodarone dose
educed after ablation were all associated with worse 1-year
T-free survival (Table 3). In multivariate analysis, no
rogrammed stimulation at the end of ablation, inducible
linical VT at the end of ablation, NIPS not performed, and
nducible clinical VT at NIPS remained independently
ssociated with VT recurrence (p  0.03, 0.003, 0.02, and
.03, respectively).
In Kaplan-Meier survival analysis, patients with inducible
linical VT at NIPS had markedly decreased 1-year VT-free
urvival (30%, p  0.001 for comparison to no VT
nducible) (Fig. 2). Importantly, 67% of these patients
xperienced recurrences with ICD shocks and 33% with VT
torm. In subgroup analysis, patients with ischemic cardio-
yopathy and those with nonischemic cardiomyopathy had
orse VT-free survival after induction of clinical VT at
IPS (p  0.01 and 0.001, respectively, for comparison to
o VT inducible). Patients with inducible nonclinical VT
ad a more modest decrease in 1- year VT-free survival,
ompared to those with no VT inducible at NIPS (65% vs.
5%; p  0.01).
iscussion
n our series of consecutive patients with structural heart
isease undergoing VT ablation, inducibility of clinical VT
t the end of ablation (n  11) and spontaneous recurrence
efore NIPS (n  11) both identified patients at high risk
f 1-year VT recurrence. However, inducibility of clinical
T at NIPS (n  24) identified an additional group of
atients at high risk of recurrence, including ICD shocks
nd VT storm, who otherwise would not have been de-
ected. We propose noninducibility of clinical VT at NIPS
s an important endpoint for VT ablation, in addition to
oninducibility of clinical VT at the end of ablation and lack
f early spontaneous recurrence. The benefit of identifying
induci
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April 24, 2012:1529–35 NIPS After VT Ablation to Predict Recurrenceadditional patients at high risk of VT recurrence includes
the potential to provide further treatment to avoid ICD
shocks and the accompanying increase in mortality (12,13).
Conversely, noninducibility of clinical VT at NIPS and—
even more so— noninducibility of any VT at NIPS allows
the clinician to provide additional reassurance to patients
who may have been psychologically traumatized by frequent
VT or ICD shocks before ablation.
Patients with clinical VT inducible at the end of ablation
are known to be at high risk of future VT recurrence, and
further ablation should be considered in this group when
possible (14,15). However, some patients may be unable to
tolerate detailed programmed stimulation at the conclusion
of a lengthy ablation procedure. Furthermore, even when
programmed stimulation can be performed at the end of
ablation, noninducibility of clinical VT at that time may fail
to identify all high-risk patients because of subsequent
changes in antiarrhythmic medications, imperfect repro-
ducibility of programmed stimulation, alterations in au-
tonomic tone and/or degree of sedation/anesthesia, and
ablation lesion maturation or regression. In support of
this, the 18 patients in our series with clinical VT
Baseline and Ablation Characteristics of Patients Stratified AccordTable 2 Baseline and Ablation Characteristics of Patients Stra
Baseline characteristics
Male
Age (yrs)
Left ventricular ejection fraction (%)
Cardiomyopathy etiology
Ischemic
Nonischemic
Right ventricular
Prior ablation
VT storm
Antiarrhythmic drug use
Amiodarone
Amiodarone 400 mg daily
Previous amiodarone, now intolerant
Non-amiodarone antiarrhythmic drug alone or in combination with amiodarone
Amiodarone dose reduced after ablation
Procedural characteristics
General anesthesia
Clinical VT inducible and sustained
Clinical VT hemodynamically tolerated
Morphologically distinct VT targeted for ablation
Endocardial ablation only
Endocardial and epicardial ablation
No programmed stimulation performed at end of ablation
Programmed stimulation performed at end of ablation
Clinical VT inducible
Nonclinical VT inducible
No VT inducible
Additional ablation procedure within same hospitalization
Values are % or mean  SD. p values are for comparison between clinical VT inducible and no VT
Abbreviations as in Table 1.inducible at NIPS who underwent programmed stimula-tion at the end of ablation did not have clinical VT
inducible at that time.
Those with clinical VT inducible at NIPS were more
likely to be taking amiodarone before ablation and more
likely to have their typically high dose of amiodarone
decreased or even discontinued after ablation. Although
reduction of the amiodarone dose is certainly an impor-
tant goal of the ablation procedure, amiodarone, partic-
ularly at high doses, may suppress some of the VT during
the ablation procedure, thereby leading to less extensive
ablation, more residual substrate, and greater risk of
recurrence during follow-up (16). It has been our clinical
observation that even an extra 3 to 4 days without
high-dose amiodarone may change the electrophysiologic
milieu, and therefore every attempt is made to withdraw
amiodarone in advance of the ablation procedure. Thus,
NIPS before discharge seems particularly important
when changes in antiarrhythmic medications are made
after ablation and when the patient’s condition is too
unstable to undergo detailed programmed stimulation at
the end of the ablation procedure.
Study strengths and limitations. Strengths of our study
o Inducibility at NIPSAccording to Inducibility at NIPS
o VT Inducible
(n  59)
Nonclinical VT Inducible
(n  49)
Clinical VT Inducible
(n  24) p Value
86.2 95.9 100.0 0.1
62.5 15.1 65.3 9.3 68.3 11.3 0.3
33.6 16.4 31.0 12.6 30.2 12.0 0.3
62.7 65.3 62.5 0.1
28.8 30.6 37.5
8.5 4.1 0
39.0 38.8 45.8 0.8
45.8 55.1 54.2 0.6
49.2 77.6 95.8 0.01
35.6 63.3 75.0 0.01
16.9 8.2 4.2 0.2
66.1 59.2 62.5 0.8
50.8 73.5 87.5 0.01
42.4 36.7 33.3 0.7
83.1 89.8 87.5 0.6
40.7 49.0 37.5 0.6
2.3 1.6 3.1 2.0 3.0 2.1 0.2
69.5 77.6 70.8 0.6
30.5 22.4 29.2
10.2 14.3 20.1 0.4
0.0 0.0 0.0
20.3 30.6 16.7 0.3
66.1 55.1 58.3 0.5
10.2 12.5 33.3 0.2
ble.ing ttified
Ninclude a sizable, contemporary cohort of patients with a
i
a
a
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NIPS After VT Ablation to Predict Recurrence April 24, 2012:1529–35mix of cardiomyopathies and careful characterization,
particularly with regard to antiarrhythmic medications
and arrhythmia episodes. Several limitations are worth
noting. First, not all patients underwent NIPS and
differences exist between those who did and did not
undergo NIPS as detailed earlier. Second, the distinction
between clinical and nonclinical VT can be problematic
as some patients do not have 12-lead electrocardiograms
of spontaneous VT, and nonclinical VTs can subse-
quently occur spontaneously (17). Nevertheless, 12-lead
ECGs of spontaneous VT episodes were available in the
majority of cases, and when not, ICD electrograms were
used to identify clinical VT, as described previously (18).
Our study looked at inducibility of VT at NIPS at one
point in time (i.e., before discharge from the hospital). It
would be interesting to study inducibility over time, as VT
substrate and antiarrhythmic milieu continue to evolve. With
22 variables undergoing univariate screening and 74 events in
follow-up, the multivariate analysis could be considered over-
fitted. Lastly, our study is observational. A prospective study
Factors Predictive of VT Recurrence After AblationTable 3 Factors Predictive of VT Recurrence After Ablation
Factor
Hazard
Ratio 95% CI p Value
Age (per 1-year increase) 1.01 0.99–1.03 0.3
Left ventricular ejection fraction
(per 1% increase)
0.98 0.97–0.99 0.04
Ischemic cardiomyopathy 0.99 0.67–1.45 0.5
Prior ablation 0.72 0.45–1.39 0.2
VT storm 1.24 0.78–1.96 0.4
Amiodarone preablation 1.32 0.81–2.16 0.3
Amiodarone 400 mg daily
preablation
1.11 0.70–1.75 0.6
General anesthesia 1.04 0.64–1.70 0.9
Clinical VT inducible and sustained 0.94 0.52–1.70 0.8
Clinical VT hemodynamically tolerated 0.62 0.38–1.01 0.1
Morphologically distinct VTs targeted
(per 1 increase)
1.05 0.93–1.78 0.4
Endocardial ablation only 1.13 0.67–1.90 0.6
No programmed stimulation performed
at end of ablation*
1.77 1.00–3.14 0.05
Clinical VT inducible at end of ablation* 3.02 1.55–5.90 0.001
Nonclinical VT inducible at end of
ablation
1.21 0.67–2.21 0.5
NIPS not performed* 1.54 0.97–2.46 0.07
Clinical VT inducible at NIPS* 2.45 1.41–2.46 0.002
Nonclinical VT inducible at NIPS 1.19 0.67–2.10 0.6
Slow VT (CL 300 ms) inducible at
NIPS
1.80 1.09–2.96 0.02
VT inducible with single or double
extrastimuli at NIPS
1.03 0.52–2.04 0.9
Polymorphic VT or ventricular flutter
inducible at NIPS
2.08 0.74–5.84 0.2
Amiodarone dose reduced after
ablation
1.76 1.08–2.89 0.02
*In multivariate modeling, no programmed stimulation at end of ablation (p  0.03), clinical VT
nducible at end of ablation (p  0.003), NIPS not performed (p  0.02), and clinical VT inducible
t NIPS (p  0.03) remained significantly associated with VT recurrence.
ATP  antitachycardia pacing; CI  confidence interval; CL  cycle length; other abbreviations
s in Table 1.examining the impact of early ablation in those with inducible
clinical VT at NIPS is needed to confirm the efficacy of this
recommendation.
Conclusions
When patients with VT and structural heart disease have no
inducible VT or inducible nonclinical VT only at the end of
ablation or are too unstable to undergo final programmed
stimulation, NIPS should be considered in the following
days in the absence of spontaneous VT to further define the
risk of arrhythmia recurrence. If clinical VT is inducible at
NIPS, repeat ablation may be indicated because recurrence
over the following year is high, including ICD shocks and
VT storm. NIPS may be of particular importance after
discontinuation or reduction of antiarrhythmic drug dose
and when programmed stimulation cannot be performed at
the end of ablation. Noninduciblity of clinical VT at NIPS
allows the clinician to more confidently reassure patients
that they are at low risk of recurrence.
Reprint requests and correspondence: Dr. Francis E. Marchlin-
ski, Hospital of the University of Pennsylvania, 9 Founders
Pavilion 3400 Spruce Street, Philadelphia Pennsylvania 19104.
E-mail: francis.marchlinski@uphs.upenn.edu.
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